Compounded Peptides ·
Outsourcing facilities registered under FDCA Section 503B differ from 503A pharmacies in both operation and regulation. They produce compounded drugs in bulk, frequently for hospital and clinic use, and must operate under cGMP-equivalent quality systems. During the tirzepatide shortage, a subset of 503B facilities became significant suppliers to office-use dispensers and to telehealth partners. FDA inspection findings through 2025 and 2026 at several 503B facilities producing compounded GLP-1s have included observations about API sourcing documentation, stability testing, and environmental monitoring — underscoring that even the more rigorous 503B pathway does not guarantee regulatory safety for compounded GLP-1s after the shortage was resolved.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.